[
  {
    "ts": null,
    "headline": "RBC Warns Gilead (GILD) Faces Risk from Trump’s Price Cut Target",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On October 1, RBC analysts stated that Gilead Sciences, Inc. (NASDAQ:GILD) may face a negative impact if its key HIV medication, Biktarvy, is targeted by the proposed price cuts mentioned by President Trump. During an announcement related […]",
    "url": "https://finnhub.io/api/news?id=d6309782940414e45994057909ffb7045df75c136861f03637b4ab2060e69563",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760644261,
      "headline": "RBC Warns Gilead (GILD) Faces Risk from Trump’s Price Cut Target",
      "id": 137121976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On October 1, RBC analysts stated that Gilead Sciences, Inc. (NASDAQ:GILD) may face a negative impact if its key HIV medication, Biktarvy, is targeted by the proposed price cuts mentioned by President Trump. During an announcement related […]",
      "url": "https://finnhub.io/api/news?id=d6309782940414e45994057909ffb7045df75c136861f03637b4ab2060e69563"
    }
  },
  {
    "ts": null,
    "headline": "Sana Biotechnology: A Big Winner In Waiting? Maybe, But It Won't Happen Overnight",
    "summary": "Sana Biotechnology, Inc. is working on a gene therapy to cure Type 1 diabetes. Click here to find out why SANA stock is a Sell.",
    "url": "https://finnhub.io/api/news?id=83780959a1c2a1ece3892e7bf9cca6270b8b829fff35f5eb545e3f402b1b0e0d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760631529,
      "headline": "Sana Biotechnology: A Big Winner In Waiting? Maybe, But It Won't Happen Overnight",
      "id": 137107868,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2174872409/image_2174872409.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Sana Biotechnology, Inc. is working on a gene therapy to cure Type 1 diabetes. Click here to find out why SANA stock is a Sell.",
      "url": "https://finnhub.io/api/news?id=83780959a1c2a1ece3892e7bf9cca6270b8b829fff35f5eb545e3f402b1b0e0d"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=0d28feaa6bcb8008107ff0e7df29b57f76ca591a4120565fec0ff81840718b00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760619605,
      "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
      "id": 137121977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=0d28feaa6bcb8008107ff0e7df29b57f76ca591a4120565fec0ff81840718b00"
    }
  }
]